Sort
4,870 grants matching “glp 1”
CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS
$2,363,015University Of Virginia Charlottesville · U54 · FY2001 · HD
Influenza vaccination using a microneedle patch
$2,319,850Mark R Prausnitz · Georgia Institute Of Technology · U01 · FY2013 · EB
Engineering commensal bacteria as therapeutic signal mediators
$2,310,000John C March · Cornell University · DP2 · FY2010 · OD
National Islet Cell Consortium Coordinating Center
$2,299,205City Of Hope/Beckman Research Institute · U42 · FY2004 · RR
HIV Subtype C Alphavirus Vaccine Design &Development
$2,270,241Alphavax Human Vaccines, Inc. · U01 · FY2002 · AI
Commercialization Readiness Program (CRP) for Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems
$2,260,835Stephen Lebeau · Nanomag, Llc · R44 · FY2020 · DE
Developing autologous iPSC-RPE based IND for AMD patients
$2,219,219Kapil Bharti · National Eye Institute · ZIA · FY2017 · EY
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,201,443Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2021 · DA
Protective Mechanisms In Cerebral Ischemia
$2,199,115John Hallenbeck · National Institute Of Neurological Disorders And Stroke · ZIA · FY2013 · NS
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
$2,194,368Carl H. June · University Of Pennsylvania · P01 · FY2021 · CA
Silica Nanocapsule-Mediated Nonviral Delivery of CRISPR Base Editor mRNA and Allele Specific sgRNA for Gene Correction in Leber Congenital Amaurosis
$2,189,363Shaoqin - Gong · University Of Wisconsin-Madison · U19 · FY2025 · NS
Developing genetically-encoded detectors for neuropeptide release based on class B G-protein coupled peptide receptors
$2,187,116Zhiping P. Pang · Rbhs-Robert Wood Johnson Medical School · RF1 · FY2019 · MH
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
$2,163,046Andrew L Salzman · Radikal Therapeutics, Inc. · R44 · FY2013 · HL
TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
$2,159,793Athan Kuliopulos · Tufts Medical Center · P50 · FY2012 · HL
RNAi Therapy for Spinocerebellar Ataxia Type 1
$2,142,201Beverly L Davidson · Children'S Hosp Of Philadelphia · UH3 · FY2017 · NS
Nonalcoholic Steatohepatitis: Natural History, Pathogenesis and Therapy
$2,131,355Yaron Rotman · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Scientific Core - Compound Optimization and Prioritization.
$2,128,141Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2020 · AI
Adeno-associated Virus Biology And Utilization For Gene Transfer
$2,128,065John A Chiorini · National Institute Of Dental & Craniofacial Research · ZIA · FY2015 · DE
Regulators of Food Intake
$2,124,191Jonathan Krakoff · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Role of G protein-coupled receptors in regulating glucose and energy homeostasis
$2,123,373Jurgen Wess · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Preclinical drug development in pancreatic cancer
$2,113,368Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease
$2,112,893Sean Ekins · Collaborations Pharmaceuticals, Inc. · SB1 · FY2025 · NS
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial
$2,100,000Judith A Kelleher-Andersson · Neuronascent, Inc. · U01 · FY2023 · AG
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial
$2,093,556Judith A Kelleher-Andersson · Neuronascent, Inc. · U01 · FY2024 · AG
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome
$2,091,549Zhiyong Yang · Fzata, Inc. · UG3 · FY2024 · NS